Agitation is a common and distressful symptom in Alzheimer's dementia. Pharmacological treatment is frequently needed when symptoms are moderate to severe. Basic etiology and pathogenesis of agitation is not well understood and this makes targeted pharmacotherapy challenging. Many drugs have been tried but FDA has not approved any drug for treatment and there is lack of consensus. We review the principles, indications and current Level I evidence on the safety and efficacy of various drugs used for treatment of agitation in Alzheimer's Dementia. We find that newer drugs like citalopram and prazosin have greater efficacy and are better tolerated than antipsychotic medications.
INTRODUCTION
Alzheimer's Dementia (AD) is a progressive neurodegenerative disease with characteristic changes in the brain that include extracellular beta amyloid deposition, intracellular neurofibrillary tangles, inflammation, loss of neuronal connections and death of neurons. Clinically, AD is characterized by a gradual onset, progressive decline in multiple cognitive functions. AD affects 5%-15% of the population over 65 years and 20% of individuals over 80 years. Over 40 % 1 of patients with AD develop psychosis, which is characterized by delusions or hallucinations and may be associated with agitation. Agitation is a cluster of related symptoms that includes anxiety, irritability, and motor restlessness, leading to behaviors such as pacing, wandering, shouting, and aggression 2 . Agitation is seen in 24% of people with AD in the community 3 and 48% of those in residential care facilities 4 . Agitation may be caused by neurodegeneration of the frontolimbic regions 5, 6 , distress due to environmental changes, illness, pain, poor sleep, depression or a side effect of medications. Agitation causes caregiver distress 7, 8 and increases risk of institutionalization 9 . Nonpharmacologic management of agitation includes ensuring a safe, calm and predictable environment, music therapy, psychomotor therapy, behavioral therapy, and distraction and avoidance techniques. However, this is of limited benefit.
Pharmacological treatment of agitation in AD is frequently needed. There are a limited number of Level I studies evaluating the safety and efficacy of various drugs. There are widely accepted recommendations that are based on limited data. FDA has not approved any medications for this purpose and there is no consensus on which drugs to use. The purpose of this manuscript is to examine the principles, indications and current Level I evidence on the safety and efficacy of various drugs used for treatment of agitation in Alzheimer's Dementia. We searched MEDLINE (Ovid SP) (1966 to date) primarily for randomized controlled trials evaluating safety and efficacy of various drugs used for treatment of agitation in AD. We reviewed the articles about the safety and efficacy, indications for use and recommendations for use of various drugs for treatment of agitation in AD.
Antipsychotics are the most commonly used drugs for agitation in AD. Typical antipsychotic drugs were used for agitation and behavioral psychotic disorders in AD starting in the 1970s. Atypical antipsychotics replaced typical antipsychotics in the 1990s because of the lower risk of motor adverse effects like tardive dyskinesia. However, atypical antipsychotics were found to be associated with a significantly increased mortality rate. This prompted FDA to issue a black-box warning about use of atypical antipsychotic agents. In recent years, other psychotropic medications have undergone clinical trials. Newer research is identifying novel targets and approaches that may be more causally related to agitation in AD.
Typical antipsychotic agents
Typical antipsychotic agents were used for agitation and behavioral psychotic disorders in AD "off-label" based on their benefits in Schizophrenia. We found 11 RCTs that evaluated the impact of typical antipsychotics versus placebo on agitation. Most trials were small, had mixed dementias and had 4-12 weeks of treatment duration. There was a significant but modest improvement compared with placebo 10 . The typical antipsychotic haloperidol was effective in improving aggression but not agitation in four RCTs. There is very little evidence base for other typical antipsychotics for treatment of these symptoms. . Eleven trials were conducted in nursing homes and four in outpatient settings. A total of 3353 patients were randomized to atypical antipsychotic treatment and 1757 to placebo group. A vast majority of subjects included had AD (87%), were women (70%) and had a mean age of 81 years. Overall, atypical antipsychotics, especially risperidone and aripiprazole improved general neuropsychiatric symptoms. However, it is difficult to separate the efficacy of these drugs on agitation or psychosis because of heterogeneity in sample (outpatient versus inpatient) and outcome measures. Subgroup analysis revealed better overall response in patients with psychosis, nursing home residents and those with severe cognitive improvement. Adverse events were mainly somnolence and urinary tract infections or incontinence with drugs and extrapyramidal symptoms or gait abnormalities with risperidone and olanzapine. There was a significant risk for cerebrovascular events especially with risperidone.
In the Clinical Antipsychotic Trial of Intervention Effectiveness study for Alzheimer's disease (CATIE-AD trial), the largest (N=421) nonindustry sponsored study of atypical antipsychotics for psychosis or agitation/aggression in people with dementia, olanzapine, quetiapine, and risperidone were no better than placebo for the primary outcome (time to discontinuation for any reason) or the secondary outcome (Clinical Global Impression or CGI) 17 . Time to discontinuation due to lack of efficacy favored olanzapine and risperidone, while time to discontinuation due to adverse events favored placebo. The CATIE-AD outcome measures assess effectiveness (not efficacy) in more clinically meaningful or relevant outcomes. This is in contrast to many previous trials, which used psychopathologic rating scales such as the Neuro-Psychiatric Inventory (NPI), Brief Psychiatric Rating Scale (BPRS), and BEHAVE-AD to assess efficacy [18] [19] [20] . The CATIE-AD trial had some limitations: 1) possible under-dosing of antipsychotics (especially regarding quetiapine) 2) the relatively high discontinuation rates compared to previous efficacy trials 15 3) all patients were outpatients and this group possibly responds less to atypical antipsychotics compared to nursing home residents or more cognitively impaired patients.
In a meta-analysis of large-scale RCTs of atypical antipsychotics in dementia, the "Number Needed to Treat" (NNT), ranged from 5 to 14 15 . The overall average treatment effect was about 18%, similar to that of typical antipsychotics 10 .
Only a few studies of antipsychotics specifically targeted agitation or aggression. Schneider 
Alpha-adrenoceptor blockers
Postmortem studies have established a relationship between altered adrenoceptors and agitation and aggression in people with AD 40 . The alpha adrenoceptor blocker prazosin has been found to be useful for treatment of BPSD in AD in a preliminary, small RCT 41 .
Conclusions
Treatment of agitation in Alzheimer's dementia is still evolving and the FDA has not approved any drugs for the same at the moment. Atypical antipsychotics have a role in short term management of these patients, but there is a significant risk of adverse events. Antidepressant agents are well tolerated but have limited evidence for efficacy in the treatment of neuropsychiatric symptoms of dementia other than depression. Overall, the published literatures based on preliminary studies support the greater efficacy of newer treatments like citalopram and prazosin and are far better tolerated than antipsychotic medications. Considering the potential for increased quality of life, these newer treatments should have a great impact on treatment of agitation worldwide. While prescribing these newer medications, doctors should work with their patients to develop a strategy that ensures maximum patient compliance. Strategies to tailor a regimen personalized to patient might serve useful. Where substitutions are not possible, supervised starts and dosage reductions may be needed.
To treat agitation in AD in more efficient and safe way, it is important to further investigate, systematically synthesize data from level I studies and estimate the safety and efficacy of various drugs used for treatment. Also, current evidences of drugs such as prazosin and citalopram are promising and large-scale clinical trials are needed. Besides, there is a need for better understanding of the basic etiology and pathogenesis of agitation and development of targeted pharmacotherapy.
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